Search

everythinglearnresearchcommunity

for

Search:↓

A 12-year-old boy with PAIS successfully developed male characteristics using high-dose testosterone and anastrozole.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Gene variation affects prostate issues and hair loss.

PON1 levels might indicate hair loss severity, but other health factors can affect this.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Genetic factors could lead to personalized treatments for hair loss.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Different levels of anti-Müllerian hormone can help diagnose polycystic ovary syndrome in women of different ages.

Finasteride may reduce prostate cancer risk.

Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Androgen-driven traits don't predict prostate cancer recurrence.

Normal levels for certain hormones in Chinese women of reproductive age were identified.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.

CEC levels may be a useful marker for predicting prostate cancer progression.

Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

High doses of cyproterone acetate are linked to an increased risk of developing meningioma.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Androgen measurement helps diagnose PCOS, but accuracy varies, needing standard methods.

A 17-year-old female with adrenogenital syndrome produces very high levels of androgens, which prevent complete feminization despite high estrogen doses.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.